Pfizer pays $15m advance on PhIII milestone for sickle cell drug
This article was originally published in Scrip
Relief for GlycoMimetics as Pfizer pays up $15m of the $35m milestone payment which was due on the start of a Phase III of the drug candidate rivipansel (GMI-1070). Pfizer however has yet to disclose when the trial of the sickle cell disease treatment will actually begin.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.